Real-world outcomes of intravitreal antivascular endothelial growth factors for neovascular age-related macular degeneration in Taiwan: A 4-year longitudinal study
PURPOSE: The purpose of the study is to report the long-term efficacy of patients with neovascular age-related macular degeneration (nAMD) treated with antivascular endothelial growth factor (VEGF) in Changhua Christian Hospital in Taiwan. MATERIALS AND METHODS: Retrospective case series of patients...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2019-01-01
|
| Series: | Taiwan Journal of Ophthalmology |
| Subjects: | |
| Online Access: | http://www.e-tjo.org/article.asp?issn=2211-5056;year=2019;volume=9;issue=4;spage=249;epage=254;aulast=Yang |
| _version_ | 1818979570719653888 |
|---|---|
| author | Benjamin Chi-Lan Yang Terry Yu-Hung Chou San-Ni Chen |
| author_facet | Benjamin Chi-Lan Yang Terry Yu-Hung Chou San-Ni Chen |
| author_sort | Benjamin Chi-Lan Yang |
| collection | DOAJ |
| description | PURPOSE: The purpose of the study is to report the long-term efficacy of patients with neovascular age-related macular degeneration (nAMD) treated with antivascular endothelial growth factor (VEGF) in Changhua Christian Hospital in Taiwan.
MATERIALS AND METHODS: Retrospective case series of patients with nAMD who were treated with intravitreal injection (IVI) of anti-VEGF and had a minimum follow-up of 48 months. Every patient was initially treated with three loading doses of either bevacizumab or ranibizumab, followed by a loose treat and extend regimen. Eyes were divided into two groups according to whether aflibercept was later used as a rescue therapy (Group 2) or not (Group 1). Patients underwent best-corrected visual acuity (BCVA) testing, optical coherence tomography, and ophthalmic examination at baseline and all the scheduled follow-up visits.
RESULTS: Seventy eyes in 63 patients were included (mean age 70.54 ± 9.18 years). The mean number of IVIs per year was 5.28 ± 1.36. The mean BCVA in logarithm of the minimal angle of resolution (logMar) improved from 0.89 ± 0.45 to 0.72 ± 0.49 for all patients (P = 0.004). Significant visual improvement was noted in Group 1 (P = 0.01) at 4 years of follow-up, but not in Group 2 (P = 0.16). Patients with initial poor BCVA (LogMar visual acuity >1.0), and older age (>70 years) had significant visual improvement, in contrast to no significant visual changes in patients with younger age and initial better BCVA.
CONCLUSION: Under a loose treat and extend protocol and rescue therapy of aflibercept, BCVA improvement was maintained for 4 years in patients with nAMD, especially in the older population (Registration Number: NCT03324542). |
| first_indexed | 2024-12-20T17:01:38Z |
| format | Article |
| id | doaj.art-d18dd1fc2ccc481bbfee0526838a2246 |
| institution | Directory Open Access Journal |
| issn | 2211-5056 2211-5072 |
| language | English |
| last_indexed | 2024-12-20T17:01:38Z |
| publishDate | 2019-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Taiwan Journal of Ophthalmology |
| spelling | doaj.art-d18dd1fc2ccc481bbfee0526838a22462022-12-21T19:32:31ZengWolters Kluwer Medknow PublicationsTaiwan Journal of Ophthalmology2211-50562211-50722019-01-019424925410.4103/tjo.tjo_34_19Real-world outcomes of intravitreal antivascular endothelial growth factors for neovascular age-related macular degeneration in Taiwan: A 4-year longitudinal studyBenjamin Chi-Lan YangTerry Yu-Hung ChouSan-Ni ChenPURPOSE: The purpose of the study is to report the long-term efficacy of patients with neovascular age-related macular degeneration (nAMD) treated with antivascular endothelial growth factor (VEGF) in Changhua Christian Hospital in Taiwan. MATERIALS AND METHODS: Retrospective case series of patients with nAMD who were treated with intravitreal injection (IVI) of anti-VEGF and had a minimum follow-up of 48 months. Every patient was initially treated with three loading doses of either bevacizumab or ranibizumab, followed by a loose treat and extend regimen. Eyes were divided into two groups according to whether aflibercept was later used as a rescue therapy (Group 2) or not (Group 1). Patients underwent best-corrected visual acuity (BCVA) testing, optical coherence tomography, and ophthalmic examination at baseline and all the scheduled follow-up visits. RESULTS: Seventy eyes in 63 patients were included (mean age 70.54 ± 9.18 years). The mean number of IVIs per year was 5.28 ± 1.36. The mean BCVA in logarithm of the minimal angle of resolution (logMar) improved from 0.89 ± 0.45 to 0.72 ± 0.49 for all patients (P = 0.004). Significant visual improvement was noted in Group 1 (P = 0.01) at 4 years of follow-up, but not in Group 2 (P = 0.16). Patients with initial poor BCVA (LogMar visual acuity >1.0), and older age (>70 years) had significant visual improvement, in contrast to no significant visual changes in patients with younger age and initial better BCVA. CONCLUSION: Under a loose treat and extend protocol and rescue therapy of aflibercept, BCVA improvement was maintained for 4 years in patients with nAMD, especially in the older population (Registration Number: NCT03324542).http://www.e-tjo.org/article.asp?issn=2211-5056;year=2019;volume=9;issue=4;spage=249;epage=254;aulast=Yangafliberceptage-related macular degenerationbevacizumablong term efficacyranibizumab |
| spellingShingle | Benjamin Chi-Lan Yang Terry Yu-Hung Chou San-Ni Chen Real-world outcomes of intravitreal antivascular endothelial growth factors for neovascular age-related macular degeneration in Taiwan: A 4-year longitudinal study Taiwan Journal of Ophthalmology aflibercept age-related macular degeneration bevacizumab long term efficacy ranibizumab |
| title | Real-world outcomes of intravitreal antivascular endothelial growth factors for neovascular age-related macular degeneration in Taiwan: A 4-year longitudinal study |
| title_full | Real-world outcomes of intravitreal antivascular endothelial growth factors for neovascular age-related macular degeneration in Taiwan: A 4-year longitudinal study |
| title_fullStr | Real-world outcomes of intravitreal antivascular endothelial growth factors for neovascular age-related macular degeneration in Taiwan: A 4-year longitudinal study |
| title_full_unstemmed | Real-world outcomes of intravitreal antivascular endothelial growth factors for neovascular age-related macular degeneration in Taiwan: A 4-year longitudinal study |
| title_short | Real-world outcomes of intravitreal antivascular endothelial growth factors for neovascular age-related macular degeneration in Taiwan: A 4-year longitudinal study |
| title_sort | real world outcomes of intravitreal antivascular endothelial growth factors for neovascular age related macular degeneration in taiwan a 4 year longitudinal study |
| topic | aflibercept age-related macular degeneration bevacizumab long term efficacy ranibizumab |
| url | http://www.e-tjo.org/article.asp?issn=2211-5056;year=2019;volume=9;issue=4;spage=249;epage=254;aulast=Yang |
| work_keys_str_mv | AT benjaminchilanyang realworldoutcomesofintravitrealantivascularendothelialgrowthfactorsforneovascularagerelatedmaculardegenerationintaiwana4yearlongitudinalstudy AT terryyuhungchou realworldoutcomesofintravitrealantivascularendothelialgrowthfactorsforneovascularagerelatedmaculardegenerationintaiwana4yearlongitudinalstudy AT sannichen realworldoutcomesofintravitrealantivascularendothelialgrowthfactorsforneovascularagerelatedmaculardegenerationintaiwana4yearlongitudinalstudy |